Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2026-02-22 @ 9:04 AM
Study NCT ID:
NCT04569032
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-12
First Post:
2020-09-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGN35-032
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None